vs

Side-by-side financial comparison of Connect Biopharma Holdings Ltd (CNTB) and Idaho Strategic Resources, Inc. (IDR). Click either name above to swap in a different company.

Connect Biopharma Holdings Ltd is the larger business by last-quarter revenue ($24.1M vs $14.6M, roughly 1.7× Idaho Strategic Resources, Inc.). Idaho Strategic Resources, Inc. runs the higher net margin — 64.3% vs 61.6%, a 2.7% gap on every dollar of revenue.

Connect Biopharma Holdings Ltd is a clinical-stage global biopharmaceutical company dedicated to developing innovative targeted therapies for inflammatory, immunological and autoimmune diseases. Its core pipeline includes candidate treatments for asthma, atopic dermatitis and other conditions with high unmet medical needs, with main operations across the U.S., China and key global markets to deliver effective therapeutic solutions to patients.

Idaho Strategic Resources, Inc. is a U.S.-based natural resource company focused on the exploration, development, and production of critical and strategic minerals. Primarily operating in Idaho, it targets rare earth elements, gold, silver, and other high-demand minerals, supplying products to the clean energy, defense, and industrial manufacturing sectors across North America.

CNTB vs IDR — Head-to-Head

Bigger by revenue
CNTB
CNTB
1.7× larger
CNTB
$24.1M
$14.6M
IDR
Higher net margin
IDR
IDR
2.7% more per $
IDR
64.3%
61.6%
CNTB

Income Statement — Q2 FY2024 vs Q4 FY2025

Metric
CNTB
CNTB
IDR
IDR
Revenue
$24.1M
$14.6M
Net Profit
$14.8M
$9.4M
Gross Margin
68.5%
Operating Margin
56.6%
62.4%
Net Margin
61.6%
64.3%
Revenue YoY
92.0%
Net Profit YoY
148.7%
220.6%
EPS (diluted)
$0.27
$0.62

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CNTB
CNTB
IDR
IDR
Q4 25
$14.6M
Q3 25
$11.1M
Q2 25
$9.5M
Q1 25
$7.3M
Q4 24
$7.6M
Q3 24
$6.2M
Q2 24
$24.1M
$6.1M
Q1 24
$5.9M
Net Profit
CNTB
CNTB
IDR
IDR
Q4 25
$9.4M
Q3 25
$3.0M
Q2 25
$2.8M
Q1 25
$1.6M
Q4 24
$2.9M
Q3 24
$1.6M
Q2 24
$14.8M
$2.2M
Q1 24
$2.2M
Gross Margin
CNTB
CNTB
IDR
IDR
Q4 25
68.5%
Q3 25
63.6%
Q2 25
57.8%
Q1 25
50.8%
Q4 24
53.3%
Q3 24
48.7%
Q2 24
50.2%
Q1 24
48.1%
Operating Margin
CNTB
CNTB
IDR
IDR
Q4 25
62.4%
Q3 25
23.4%
Q2 25
26.6%
Q1 25
19.3%
Q4 24
36.2%
Q3 24
23.4%
Q2 24
56.6%
34.2%
Q1 24
36.3%
Net Margin
CNTB
CNTB
IDR
IDR
Q4 25
64.3%
Q3 25
26.8%
Q2 25
29.2%
Q1 25
22.1%
Q4 24
38.5%
Q3 24
25.8%
Q2 24
61.6%
35.2%
Q1 24
36.8%
EPS (diluted)
CNTB
CNTB
IDR
IDR
Q4 25
$0.62
Q3 25
$0.20
Q2 25
$0.20
Q1 25
$0.12
Q4 24
$0.21
Q3 24
$0.12
Q2 24
$0.27
$0.17
Q1 24
$0.17

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CNTB
CNTB
IDR
IDR
Cash + ST InvestmentsLiquidity on hand
$110.2M
Total DebtLower is stronger
$2.3M
Stockholders' EquityBook value
$110.9M
$108.2M
Total Assets
$120.6M
$116.2M
Debt / EquityLower = less leverage
0.02×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CNTB
CNTB
IDR
IDR
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
$110.2M
$6.3M
Q1 24
$5.3M
Total Debt
CNTB
CNTB
IDR
IDR
Q4 25
$2.3M
Q3 25
$3.0M
Q2 25
$3.3M
Q1 25
$3.7M
Q4 24
$1.7M
Q3 24
$2.9M
Q2 24
$2.7M
Q1 24
$3.3M
Stockholders' Equity
CNTB
CNTB
IDR
IDR
Q4 25
$108.2M
Q3 25
$74.3M
Q2 25
$49.3M
Q1 25
$39.8M
Q4 24
$37.7M
Q3 24
$33.1M
Q2 24
$110.9M
$25.4M
Q1 24
$21.6M
Total Assets
CNTB
CNTB
IDR
IDR
Q4 25
$116.2M
Q3 25
$83.1M
Q2 25
$57.7M
Q1 25
$48.1M
Q4 24
$44.0M
Q3 24
$40.8M
Q2 24
$120.6M
$32.2M
Q1 24
$28.7M
Debt / Equity
CNTB
CNTB
IDR
IDR
Q4 25
0.02×
Q3 25
0.04×
Q2 25
0.07×
Q1 25
0.09×
Q4 24
0.05×
Q3 24
0.09×
Q2 24
0.11×
Q1 24
0.15×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CNTB
CNTB
IDR
IDR
Operating Cash FlowLast quarter
$-8.0M
$10.7M
Free Cash FlowOCF − Capex
$8.2M
FCF MarginFCF / Revenue
56.0%
Capex IntensityCapex / Revenue
17.7%
Cash ConversionOCF / Net Profit
-0.54×
1.15×
TTM Free Cash FlowTrailing 4 quarters
$12.4M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CNTB
CNTB
IDR
IDR
Q4 25
$10.7M
Q3 25
$2.4M
Q2 25
$3.5M
Q1 25
$2.4M
Q4 24
$3.2M
Q3 24
$2.5M
Q2 24
$-8.0M
$2.6M
Q1 24
$2.6M
Free Cash Flow
CNTB
CNTB
IDR
IDR
Q4 25
$8.2M
Q3 25
$709.8K
Q2 25
$2.5M
Q1 25
$1.0M
Q4 24
$2.1M
Q3 24
$1.9M
Q2 24
$2.4M
Q1 24
$2.3M
FCF Margin
CNTB
CNTB
IDR
IDR
Q4 25
56.0%
Q3 25
6.4%
Q2 25
26.5%
Q1 25
13.8%
Q4 24
28.0%
Q3 24
30.4%
Q2 24
38.7%
Q1 24
38.3%
Capex Intensity
CNTB
CNTB
IDR
IDR
Q4 25
17.7%
Q3 25
15.3%
Q2 25
10.8%
Q1 25
19.4%
Q4 24
13.6%
Q3 24
9.8%
Q2 24
4.3%
Q1 24
5.5%
Cash Conversion
CNTB
CNTB
IDR
IDR
Q4 25
1.15×
Q3 25
0.81×
Q2 25
1.28×
Q1 25
1.50×
Q4 24
1.08×
Q3 24
1.56×
Q2 24
-0.54×
1.22×
Q1 24
1.19×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons